Umm salal: A recent scientific study has highlighted researchers' progress toward developing a vaccine that protects against the Epstein-Barr virus (EBV), a common virus associated with infectious mononucleosis, multiple sclerosis, certain types of cancer, and other serious diseases, after successfully testing laboratory-developed antibodies in mice.

According to Qatar News Agency, the study, published in Cell Reports Medicine, reported that the researchers developed ten antibodies, each targeting one of two proteins on the surface of the virus. The first protein, known as gp350, enables the virus to bind to cellular receptors, while the second, gp42, facilitates viral entry into cells.

The study explained that one antibody directed against gp42 demonstrated efficacy in preventing infection when mice with humanized immune systems were exposed to the Epstein-Barr virus. Another antibody targeting gp350 contributed to partial protection. Dr. Andrew McGuire, one of the study authors from the Fred Hutchinson Cancer Center, said that after many years of searching for an effective way to protect against the Epstein-Barr virus, these findings represent an important step forward for the scientific community and for individuals at higher risk of complications associated with this virus.

For her part, Dr. Rachel Bender Ignacio, a physician and co-author of the study, emphasized that effective prevention of Epstein-Barr virus presence in the bloodstream remains an urgent need. She added that the vaccine would make a significant difference.